Journal of breast cancer research最新文献

{"title":"Uncovering genetic variations in HTR2A and miRNAs drivers of breast cancer risk in African American women.","authors":"Nicole Retland, Karl M Thompson, Joseph I Aubee, Victor Apprey, Somiranjan Ghosh, Robert Copeland, Yasmine Kanaan, Yayin Fang, Ali Ramadan, Hassan Brim, Muneer M Abbas","doi":"10.46439/breastcancer.6.037","DOIUrl":"10.46439/breastcancer.6.037","url":null,"abstract":"<p><strong>Background/objectives: </strong>Triple-negative breast cancer (TNBC) disproportionately affects African American (AA) women, yet the molecular mechanisms remain poorly understood. Emerging evidence suggests that microRNAs (miRNAs) may play a critical role in cancer progression. This study investigated the association of HTR2A genetic variants and miRNA dysregulation in AA women with breast cancer.</p><p><strong>Methods: </strong>A total of 417 AA women (192 with breast cancer, 225 controls) were genotyped for selected HTR2A SNPs. Functional predictions and molecular modeling assessed structural impact. TNBC cell lines were treated with an HTR2A agonist, and miRNA expression was profiled using the NanoString, and bioinformatic tools were applied to identify miRNA targets and associated oncogenic pathways.</p><p><strong>Results: </strong>Three SNPs (rs6304, rs6311, and rs1745837) were significantly associated with breast cancer risk (e.g., rs6311 dominant model: OR = 11.98, 95% CI: 6.63-21.66, p < 0.0001). The rs6304 demonstrated predicted protein destabilization. Six oncogenic miRNAs (including miR-92a-3p and miR-377-3p) were significantly upregulated (p < 0.05) and involved in PI3K/AKT, JAK/STAT, and IL-6 pathways.</p><p><strong>Conclusions: </strong>HTR2A genetic variation, miRNA dysregulation, and increased breast cancer risk in AA women. These findings suggest that HTR2A variants and miRNA profiles may serve as potential biomarkers for risk stratification and targeted therapeutic approaches in TNBC.</p><p><strong>Simple summary: </strong>African American women face a higher risk of developing a particularly aggressive type of breast cancer called TNBC. This study explores how changes in a specific serotonin receptor gene, known as HTR2A, might contribute to this risk. By analyzing the DNA of AA women and conducting lab experiments, the researchers identified genetic variations that are more common in women with breast cancer. They also discovered that these genetic changes may affect the way small molecules called microRNAs control cell growth. Understanding these links may help scientists find better ways to detect and treat breast cancer in AA women, paving the way for more personalized and effective medical care.</p>","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"6 1","pages":"65-83"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13618301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the role of HSP90 in cancer cell phenotypic plasticity.","authors":"Vincent Sollars, Alexandria Chapman, Nicole R Liang, Seth Myers","doi":"10.46439/breastcancer.4.021","DOIUrl":"10.46439/breastcancer.4.021","url":null,"abstract":"<p><p><i>\"What are the mechanisms driving tumor evolution under the selective pressure of chemotherapeutics?\"</i> The emerging importance of epigenetic gene regulation in cancer progression necessitates not only our understanding of which genes are potential targets but also what mechanisms are employed in targeting those genes. Understanding the mechanisms that promote the evolution of the normal genome and epigenome is central to understanding how cancer cells adapt to chemotherapy. Our previous investigations have shown that heat shock protein 90 (HSP90) has a critical role in epigenetic gene regulation through histone acetylation and phenotypic plasticity. We recently extended these results in an A549 lung cancer model to test the role of HSP90 in the plasticity of cells regarding multi-drug resistance and epithelial-to-mesenchymal transition phenotypes. HSP90 is over-expressed in multiple cancers with poor prognosis. We propose that inhibition of HSP90 results in lower phenotypic plasticity of cancer cells making them more susceptible to chemotherapeutic intervention. Here we review the context of our results in the broader field of evolution of these phenotypes.</p>","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"4 1","pages":"5-10"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic breast cancer-derived exosomes and osteoclast-mediated bone metastasis","authors":"Manh Tien Tran","doi":"10.46439/breastcancer.3.019","DOIUrl":"https://doi.org/10.46439/breastcancer.3.019","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"296 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72504281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new population screening program for BRCA mutations in Israel – Attitudes and barriers among Ashkenazi Jewish women","authors":"Amar S, Lieberman S, Biderman A, Lahad A, Feinsilver T","doi":"10.46439/breastcancer.2.011","DOIUrl":"https://doi.org/10.46439/breastcancer.2.011","url":null,"abstract":"Israeli Jewish women of Ashkenazi ancestry have a high BRCA mutation carrier rate. Therefore, recently, Israel included free genetic testing among all Jewish women with Ashkenazi ancestry, 25 yrs. and older in its public health system. The aim of this study was to assess the intention of eligible women to be tested for BRCA mutations, and to find factors that may affect their decision.\u0000\u0000We distributed an online survey to a panel of participants in a commercial research institute. The survey included socio-demographic characteristics, attitudes towards preventive actions, views related to benefits and limitations of performing the BRCA test, worry regarding cancer morbidity, knowledge about breast cancer morbidity and hereditary breast cancer genetics. The survey concluded with a question regarding the woman’s interest in undergoing the BRCA test.\u0000\u0000The results showed that among the 506 respondents, 250 (49%) were interested in BRCA testing, 42 (8%) objected and 214 (43%) were undecided. In comparing the undecided to the other groups, we found that most presented a positive attitude towards screening tests and preventive medicine, they showed acceptable knowledge about the proposed test, and yet were interested in learning and further expanding the knowledge and the consequences of doing the test. Most respondents of all groups expressed concern of breast cancer morbidity and were reluctant to perform the test for reasons of reducing uncertainty, implications for children and implications for their own health.\u0000\u0000Within all groups, many women expressed their desire to consult with a medical professional about the test. We conclude that aiming to improve the performance of BRCA genetic testing, women need a thorough explanation about its implications. The main way to inform them would be by medical professionals, especially in primary care. This implies that front line nurses and physicians need to become more knowledgeable and committed to this subject.","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81971319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor grade as a novel predictor of outcomes in medullary thyroid cancer","authors":"Aradhya Nigam, B. Untch, A. Shaha","doi":"10.46439/breastcancer.3.017","DOIUrl":"https://doi.org/10.46439/breastcancer.3.017","url":null,"abstract":"The recent development of the International Medullary Thyroid Cancer Grading System (IMTCGS) provided clinicians with a tool to predict for disease outcomes after undergoing resection based on histologic features. However, its impact on the clinical management of patients is still under investigation. Utilizing the IMTCGS, we evaluated the association of grade with postoperative surveillance markers. High-grade tumors, when compared to low-grade, had a significantly more rapid calcitonin doubling time with a vast majority of high-grade patients having doubling times <2 years. While these findings reaffirmed the poor recurrence and mortality outcomes observed in high-grade patients, we found that high-grade patients with rapid calcitonin doubling times were particularly at risk for poor local control and survival outcomes.These findings demonstrate the importance of close clinical follow-up of patients with high-grade disease and further support the determination tumor grade and calcitonin doubling times in MTC patients after resection. In addition, the study supports the use of MTC grading as an important variable for future management of MTC patients. This could lay the foundation for better understanding of neuroendocrine carcinomas of the breast.","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80422003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loss of breast reconstruction services during the COVID-19 pandemic: Negative impact on patient quality of life and wellbeing","authors":"Jenna Shepherd, Mairi Fuller, Sue Rodwell, Rachel Moir, Beatrix Elsberger, Yazan A. Masannat","doi":"10.46439/breastcancer.2.012","DOIUrl":"https://doi.org/10.46439/breastcancer.2.012","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136012191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in shared decision-making for breast cancer screening in Spain","authors":"María José Hernández-Leal, M. Pérez-Lacasta, M. Carles-Lavila","doi":"10.46439/breastcancer.2.013","DOIUrl":"https://doi.org/10.46439/breastcancer.2.013","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90535955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoangiogenesis and immune-regulation: Two armour of VEGF in the tumor microenvironment","authors":"Subhanki Dhar, Tania Sarkar, G. Sa","doi":"10.46439/breastcancer.2.015","DOIUrl":"https://doi.org/10.46439/breastcancer.2.015","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91043283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncologist well-being in the era of COVID-19: A call to action","authors":"A. Chichura, K. Yao","doi":"10.46439/breastcancer.2.010","DOIUrl":"https://doi.org/10.46439/breastcancer.2.010","url":null,"abstract":"","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"131 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77613723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NTRK fusions: A novel diagnostic and therapeutic methodology for cancer","authors":"Rishika Singh, Nupur Singh, G. Vidal","doi":"10.46439/breastcancer.3.016","DOIUrl":"https://doi.org/10.46439/breastcancer.3.016","url":null,"abstract":"This commentary discusses the case from the publication “Metastatic Triple Negative Breast Cancer with NTRK Gene Fusion on Tissue but not on ctDNA Molecular Profile.” This paper stresses the importance of molecular profiling to find characteristic mutations such as NTRK gene fusions which increase therapeutic options including tyrosine receptor kinase inhibitors such as Larotrectinib and entrectinib. The current profiling techniques are also discussed with both advantages and limitations discussed. Genomic testing in relation to current pharmaceutical therapies will shape the future of cancer diagnosis and treatment.","PeriodicalId":73629,"journal":{"name":"Journal of breast cancer research","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76994742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}